Meditati
Smart drugs for mental health.
Learn more
About Us
Mission
We have developed a drug design algorithm, integrated within our therapeutic discovery platform, CANDO (Computational Analysis of Novel Drug Opportunities), which leverages multiscale data to rapidly generate unique, effective, and safe drugs de novo. The novelty of this approach lies in the use of full organismal proteomes to tailor molecules for specific therapeutic uses, while considering toxicity and other pharmacological properties. This approach is in direct contrast to traditional drug discovery pipelines in which a single protein target is used in a large-scale screen of compounds/drugs for a single disease/indication.
With CANDO, we will generate drug candidates that enhance quality of life (such as improving cognition and reducing pain) with negligible side effects (such as reducing substance abuse potential).
Leadership
William Mangione, Ph.D.
CEO and co-founder
Zackary Falls, Ph.D.
CSO and co-founder
Brennan Overhoff
COO and co-founder
Matthew Muhoberac
Co-founder
Gaurav Chopra, Ph.D.
Co-founder
Ram Samudrala, Ph.D.
Co-founder
Scientific Advisors
Jun-Xu Li, Ph.D.
Scientific Advisor
Peter Thanos, Ph.D.
Scientific Advisor
Media and Publications
Shotgun Drug Repurposing Aids Fight Against COVID-19
University at Buffalo School of Medicine2020 NCATS ASPIRE Reduction-to-Practice Challenge Winners
National Center for Advancing Translational Sciencescando.py: Open Source Software for Predictive Bioanalytics of Large Scale Drug–Protein–Disease Data
Journal of Chemical Information and ModelingPipeline
Lead design
Lead synthesis
Preclinical
Phase I
Phase II
Phase III
Substance use disorder
Non-addictive analgesics
Cognition enhancement